首页> 中文期刊> 《中国当代医药》 >血栓抽吸术联合择期经皮冠状动脉介入治疗急性心肌梗死的临床效果及安全性分析

血栓抽吸术联合择期经皮冠状动脉介入治疗急性心肌梗死的临床效果及安全性分析

         

摘要

目的:探讨在急性心肌梗死治疗中采用择期经皮冠状动脉介入治疗联合血栓抽吸术的临床效果及安全性。方法选取本院2012年3月~2014年3月收治的80例急性心肌梗死患者作为研究对象,随机分为观察组和对照组,各40例。对照组行择期经皮冠状动脉介入治疗,观察组在对照组的基础上联合血栓抽吸术治疗,比较两组的治疗效果、治疗前后相关指标变化情况、急性期不良事件发生情况及预后情况。结果观察组的总有效率显著高于对照组,差异有统计学意义(P<0.05)。观察组治疗后的AST与LDH水平显著低于对照组,差异有统计学意义(P<0.05)。观察组的急性期不良事件发生率显著低于对照组,差异有统计学意义(P<0.05)。观察组6个月后的心脏事件发生率显著低于对照组,差异有统计学意义(P<0.05)。结论择期经皮冠状动脉介入治疗联合血栓抽吸术治疗急性心肌梗死效果显著,能有效改善患者心肌功能,降低心脏事件发生率,安全性高,值得临床推广应用。%Objective To explore the clinical efficacy and safety of percutaneous coronary intervention (PCI) in selec-tive time combined with thrombus aspiration in the treatment of acute myocardial infarction (AMI). Methods 80 pa-tients with ACI in our hospital from March 2012 to March 2014 were selected and randomly divided into the observa-tion group and the control group ,40 cases in each group.The control group was treated with PCI in selective time,the observation group was treated with thrombus aspiration on the basis of the control group.The therapeutic effect,changes of related indicators before and after treatment,occurrence of adverse events at acute phase and prognosis in two groups were compared. Results The total effective rate in the observation group was higher than that in the control group,with significant difference (P<0.05).The level of aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) after treat-ment in the observation group were lower than that in the control group,with significant difference (P<0.05).The incidence of adverse events at acute phase in the observation group was lower than that in the control group,with significant dif-ference (P<0.05).The incidence of cardiac events after treatment at 6 months in the observation group was lower than that in the control group,with significant difference (P<0.05). Conclusion The effect of thrombus aspiration combined with percutaneous coronary intervention in selective time in the treatment of acute myocardial infarction is significant, which can improve patient’s cardiac function and reduce the incidence of cardiac events,it is worthy of clinical promo-tion and application.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号